Symbols

IMUX

Immunic·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMUX

Immunic, Inc.

A biotech company that develops and commercializes oral immunotherapies for autoimmune diseases in the US and Europe

Industry

Biological Technology

Established Date

05/23/2003

Listing Date

04/17/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.imux.com

Security Type

Common stock

Office address

1200 Avenue of the Americas Suite 200 New York NY 10036

Business

Introduction

Immunic, Inc., through the acquisition of the assets and operations of VitaGen Corporation, commenced operations as a California corporation on May 23, 2003 and changed its name to Vital Therapies, Inc., in June 2003. In January 2004, the company was incorporated again in Delaware. Immunic is a late-stage biotechnology company focused on the development of novel oral therapies for the treatment of neurological and gastrointestinal diseases. The company is headquartered in New York City, with principal operations in Graffelfen, near Munich, Germany. Immunic is committed to advancing the clinical development of small molecule drug programs designed to meet the unmet medical needs of patients with severe chronic inflammation and autoimmune diseases. This includes the vidofludimus calcium program (for the treatment of relapsing multiple sclerosis patients), which is currently in phase III clinical development, as well as other programs for various gastrointestinal and autoimmune diseases.

Company Financials

EPS

IMUX has released its 2025 Q4 earnings. EPS was reported at -0.62, versus the expected -0.09, missing expectations. The chart below visualizes how IMUX has performed over recent quarters, highlighting trends in earnings surprises.